<DOC>
	<DOCNO>NCT01222520</DOCNO>
	<brief_summary>If patient blood pressure control telmisartan 80 mg , antihypertensive drug different class start concomitantly . In Japanese 3x3 factorial trial telmisartan hydrochlorothiazide essential hypertension patient whose diastolic blood pressure ( DBP ) equal 95 mmHg , DBP control rate ( le 90 mmHg ) 8 week treatment telmisartan 80 mg monotherapy group ( 66 patient ) 41.5 % . There medical need telmisartan 80 mg amlodipine 5 mg fix dose combination patient blood pressure control telmisartan 80 mg . Thus , clinical trial conduct evaluate antihypertensive effect safety fixed-dose combination ( FDC ) drug 2 antihypertensive agent different pharmacological effect , telmisartan 80 mg amlodipine 5 mg ( T80/A5 mg ) , compare telmisartan 80 mg ( T80 mg ) monotherapy Japanese patient essential hypertension fail respond adequately treatment maximum dose telmisartan 80 mg monotherapy . In trial , multi-centre , randomise , double-blind , double-dummy , active-controlled , parallel group comparison method employ .</brief_summary>
	<brief_title>Telmisartan 80mg Non-responder Trial</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Inclusion criterion : Essential hypertensive patient If already take antihypertensive drug , mean seat diastolic blood pressure ( DBP ) must &gt; =90 &gt; =114 mmHg If take antihypertensive drug , mean seat DBP must &gt; =95 &gt; =114 mmHg Able stop current antihypertensive drug without risk patient base investigator opinion . Exclusion criterion : Patients take 3 antihypertensive drug sign informed consent form Patients know suspected secondary hypertension Patients clinically relevant cardiac arrhythmia Congestive heart failure New York Heart Association ( NYHA ) functional class IIIIV Patients recent cardiovascular event Patients history stroke transient ischaemic attack within last 6 month sign informed consent form Patients history sudden deterioration renal function angiotensin II receptor blocker ( ARBs ) angiotensin convert enzyme ( ACE ) inhibitor ; patient postrenal transplant postnephrectomy Patients previously experience characteristic symptom angioedema ( facial , tongue , pharyngeal , laryngeal swell dyspnea ) treatment ARBs ACE inhibitor Patients know hypersensitivity component investigational product , know hypersensitivity dihydropyridinederived drug Patients hepatic and/or renal dysfunction Premenopausal woman nurse pregnant</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>